EGFR and interstitial lung disease: Mamesaya et al.23 reported a case of a 38-year-old female patient with osimertinib-induced ILD after treatment with anti-PD1 antibody and speculated anti-PD1 therapies might be the risk factor of EGFR-TKI-induced ILD.